StockNow
Calendar
Log in
U.S. Markets

Amgen (AMGN) receives FDA warning letter for Vectibix misbranding

ORIGINAL · NewsquawkAmgen (AMGN) receives FDA warning letter for Vectibix misbranding
StockNow breaking-news AI analysis

The supplied headline reports an FDA warning letter to Amgen concerning Vectibix misbranding; no details of the letter or company response are available in the retrieved record.

1 stocks
AMGNAmgen Inc$446.49Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Saudi fighter jets attack Bab al-Mandab, reports Tasnim

Politics

Russian Foreign Minister Lavrov says the Ukraine conflict is likely to continue and will likely escalate. Leaders of Finland and Norway raised no new proposals

U.S. Markets

Constellation Energy (CEG) has been offered USD 5bln in financing by the US government for nuclear reactors

CEG